Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Axl-1717. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 5/20 | 1.00 |
| ▸ | TUBB | P07437 | 5/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 5/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 5/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 5/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 5/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 5/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 1.00 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Podofilox SCHEMBL12377923 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL30947382 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL10005569 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL13663652 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL10046308 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Epipodophyllotoxin SCHEMBL5792464 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL24049951 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL42243 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL13661743 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL20807187 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739392-A1 | METHODS OF TREATING ACTIVE AND CHRONIC THYROID EYE DISEASE | Viridian Therapeutics, Inc. (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-4593956-A1 | METHODS FOR TREATING INACTIVE OR CHRONIC THYROID EYE DISEASE | Horizon Therapeutics Ireland DAC (IE) | 2025-08-06 | — | — | EP | claimed |
| WO-2025106903-A1 | THE ROLE OF MIR-15A IN DIAGNOSING AND TREATING PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) | OHIO STATE INNOVATION FOUNDATION (US) | 2025-05-22 | — | — | WO | claimed |
| US-20250161287-A1 | METHODS, COMPOSITIONS, AND COMBINATIONS FOR PREVENTING OR TREATING CANCER RECURRENCE | VUJA DE SCIENCES INC (US) | 2025-05-22 | — | — | US | claimed |
| EP-4532551-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF THYROID EYE DISEASE | Horizon Therapeutics Ireland DAC (IE) | 2025-04-09 | — | — | EP | claimed |
| WO-2025014774-A9 | METHODS OF TREATING ACTIVE AND CHRONIC THYROID EYE DISEASE | Viridian Therapeutics, Inc. (US) | 2025-03-06 | — | — | WO | claimed |
| WO-2025034898-A1 | GASTRIC CANCER PATIENT CLASSIFICATION AND METHODS OF TREATMENT | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-02-13 | — | — | WO | claimed |
| WO-2025014774-A1 | METHODS OF TREATING ACTIVE AND CHRONIC THYROID EYE DISEASE | Viridian Therapeutics, Inc. (US) | 2025-01-16 | — | — | WO | claimed |
| CN-1543466-A | Novel use of specific cyclolignans | — | 2004-11-03 | — | — | CN | claimed |
| US-20040186169-A1 | Use of specific cyclolignans | AXELAR AB (SE) | 2004-09-23 | — | — | US | claimed |
| WO-2004055022-A1 | USE OF CYCLOLIGNANS AS INHIBITORS OF IGF-1 RECEPTOR FOR TREATMENT OF MALIGNAT DISEASES | BIOVITRUM AB (SE) | 2004-07-01 | — | — | WO | claimed |
| EP-1397368-A1 | NEW USE OF SPECIFIC CYCLOLIGNANS | Axelar AB (SE) | 2004-03-17 | — | — | EP | claimed |
| CN-1139593-C | 3 alpha-bromoepipodophyllotoxin, its position-4 substituted derivative and preparing process thereof | 国家医药管理局上海医药工业研究院 | 2004-02-25 | — | — | CN | claimed |
| CN-1410425-A | Derivative containing nitrogen oxygen free radical picropodophyllin | CHEN SHAOMING (CN) | 2003-04-16 | — | — | CN | claimed |
| WO-2002102804-A1 | NEW USE OF SPECIFIC CYCLOLIGNANS | AXELAR AB (SE) | 2002-12-27 | — | — | WO | claimed |
| EP-1251858-A2 | PODOPHYLLOTOXIN COMPOSITIONS | SUPRATEK PHARMA INC. (CA) | 2002-10-30 | — | — | EP | claimed |
| CN-1338457-A | 3 alpha-bromoepipodophyllotoxin, its position-4 substituted derivative and preparing process thereof | SHANGHAI INST OF MECICAL INDUS (CN) | 2002-03-06 | — | — | CN | claimed |
| WO-2001052826-A2 | NOVEL PODOPHYLLOTOXIN COMPOSITIONS | SUPRATEK PHARMA INC. (US) | 2001-07-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186169-A1 | Use of specific cyclolignans | IGF1R, IGFBP1, PIN1 | LMNA 4301/4885CYP3A4 3367/4885TUBB4A 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.